%PDF-1.4
%
50 0 obj
<>
endobj
162 0 obj
<>/Font<>>>/Fields[]>>
endobj
47 0 obj
<>
endobj
29 1 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T16:31:39Z
2024-03-28T06:36:25-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T06:36:25-07:00
application/pdf
Heather
2001-806.nov02
uuid:231c6438-1dd2-11b2-0a00-b409277d8900
uuid:231c643a-1dd2-11b2-0a00-d30000000000
endstream
endobj
36 0 obj
<>
endobj
37 0 obj
<>
endobj
51 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
186 0 obj
[190 0 R]
endobj
187 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.02271 Tw 10 0 0 10 54 713.1616 Tm
[(phase of repair)54.9 (. )54.9 (An example of such is the regulation of ar)17.9 (gi-)]TJ
0.0295 Tw 0 -1.2 TD
(nine metabolism in wound healing)Tj
0 Tw 6.5 0 0 6.5 193.4882 704.4615 Tm
(21)Tj
0.0295 Tw 10 0 0 10 199.9882 701.1616 Tm
[(, during which ar)17.8 (ginine)]TJ
0.0378 Tw -14.5988 -1.2 Td
(is first metabolized through the iNOS pathway and then, as)Tj
0.1277 Tw T*
[(the healing process starts to occur)39.8 (, the inflammatory cells)]TJ
-0.03709 Tw T*
[(present at the site divert the ar)17.8 (ginine metabolism towards the)]TJ
0.02499 Tw T*
[(ar)17.8 (ginase pathway)64.9 (, polyamine synthesis, and tissue repair)54.9 (.)]TJ
-0.0211 Tw 1.2 -1.2 Td
[(This suggests that ar)17.8 (ginase upregulation may be involved)]TJ
0.291 Tw -1.2 -1.2 Td
[(in cell proliferation or recovery)64.9 (, since )17.8 (TGF-\337 promotes)]TJ
-0.00011 Tc -0.03149 Tw T*
(fibroblast proliferation in RA)Tj
0 Tc 0 Tw 6.5 0 0 6.5 170.5133 620.4615 Tm
(22)Tj
-0.03149 Tw 10 0 0 10 179.1982 617.1616 Tm
(and also contributes to extra-)Tj
0.02 Tc 0.4417 Tw -12.5198 -1.2 Td
(cellular matrix remodeling, including stimulation of)Tj
-0.00011 Tc 0.1658 Tw T*
(collagen synthesis by fibroblasts)Tj
0 Tc 0 Tw 6.5 0 0 6.5 189.2143 596.4615 Tm
(23)Tj
0.1657 Tw 10 0 0 10 195.7142 593.1616 Tm
(. Ornithine, synthesized)Tj
0.1711 Tw -14.1714 -1.2 Td
[(by ar)17.8 (ginase, is necessary for the production of collagen)]TJ
0 Tw 6.5 0 0 6.5 288.2502 584.4615 Tm
(6)Tj
10 0 0 10 291.5002 581.1616 Tm
(,)Tj
-0.00011 Tc 0.0197 Tw -23.75 -1.2 Td
(which also occurs in RA, where collagen type II expression)Tj
0 Tc 0.02499 Tw T*
(has been found)Tj
0 Tw 6.5 0 0 6.5 115.0323 560.4615 Tm
(24)Tj
10 0 0 10 121.5322 557.1616 Tm
(.)Tj
0.19 Tw -5.5532 -1.22 Td
[(In conclusion, we found ar)17.8 (ginase II induction in cells)]TJ
-0.00011 Tc -0.0152 Tw -1.2 -1.22 Td
[(from patients with dif)17.7 (ferent forms of arthritis. In cells where)]TJ
0.02811 Tw 0 -1.22 TD
[(both ar)17.7 (ginase II and iNOS are induced, there is a reciprocal)]TJ
0 Tc 0.2789 Tw T*
(regulation, which suggests that the relative activities of)Tj
-0.00011 Tc 0.0683 Tw T*
[(ar)17.7 (ginase and iNOS reflect dif)17.7 (ferent stages in the pathology)]TJ
0 Tc 0.03571 Tw T*
[(of chronic inflammatory diseases. Regulation of ar)17.8 (ginase II)]TJ
0.2507 Tw T*
(induction in human arthritis could be very important in)Tj
0.18401 Tw T*
[(determining the progression of the disease; ef)17.8 (forts are in)]TJ
-0.00011 Tc 0.33749 Tw T*
(progress in our laboratory to better assess the role of)Tj
0 Tc 0.02499 Tw T*
[(ar)17.8 (ginase in inflammatory joint diseases.)]TJ
/TT1 1 Tf
-0.0101 Tc 0.2812 Tw 0 -2.4 TD
[(ADDED IN PROOF)91.7 (.)]TJ
/TT0 1 Tf
9.7568 0 Td
(Subsequent to acceptance of their)Tj
0.05659 Tw -9.7568 -1.2 Td
(revised manuscript, Drs. Corraliza and Moncada identified a)Tj
0.0547 Tw 0 -1.2 TD
[(new reference regarding increased levels of ar)18 (ginase activity)]TJ
0.2485 Tw T*
[(in patients with RA. However)39.9 (, as only the abstract is in)]TJ
0.0576 Tw T*
(English, they have been unable to appropriately evaluate the)Tj
0.31281 Tw T*
(work and cannot therefore include it in their discussion)Tj
-0.0049 Tw T*
(although they wish to acknowledge it among their references.)Tj
0 Tc 0.08369 Tw T*
[(Huang L)74 (W)91.8 (, Chang KL, Chen CJ, Liu HW)91.8 (. )54.9 (Ar)17.8 (ginase levels)]TJ
0.02 Tc 0.48421 Tw T*
(are increased in patients with rheumatoid arthritis.)Tj
0 Tc 0.02499 Tw T*
[(Gaoxioing )36.9 (Y)55.2 (i Xue Ke Xue Za Zhi 2001;17:358-63.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0.00391 Tc 0.371 Tw 8 0 0 8 54 269.1617 Tm
[(W)79.8 (e thank Professor J. Edwards and Dr)55 (. )54.8 (A. Bhatia \(Department of)]TJ
0 Tc 0.06821 Tw 0 -1.25 TD
[(Rheumatology)64.9 (, UCL, UK\) for providing the synovial fluid and tissue and)]TJ
0.2662 Tw T*
[(Dr)54.9 (. G. Chaudhuri \(Department of Obstetrics and Gynecology)65 (, UCLA,)]TJ
-0.00011 Tc 0.0699 Tw T*
[(USA\) for providing the sequence of the primers for ar)17.7 (ginase I and II. )17.8 (W)79.7 (e)]TJ
0 Tc 0.0249 Tw T*
[(thank Mrs. )54.8 (A. Higgs for helping in preparation of the manuscript.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 54 207.1617 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 60.8 197.1617 Tm
[(1.)-600 (Panayi GS. )17.7 (T)91.8 (-cell-dependent pathways in rheumatoid arthritis. Curr)]TJ
1.35 -1.25 Td
(Opin Rheumatol 1997;9:236-40.)Tj
-1.35 -1.25 Td
[(2.)-600 (Cochran FR, Selph J, Sherman P)110.8 (. Insights into the role of nitric)]TJ
1.35 -1.25 Td
(oxide in inflammatory arthritis. Med Res Rev 1996;16:547-63.)Tj
-1.35 -1.25 Td
[(3.)-600 (Ialenti )54.9 (A, Moncada S, Di Rosa M. Modulation of adjuvant arthritis)]TJ
1.35 -1.25 Td
[(by endogenous nitric oxide. Br J Pharmacol 1993;1)36.9 (10:701-6.)]TJ
-0.00011 Tc -1.35 -1.25 Td
[(4.)-600.1 (Farrell )54.8 (AJ, Blake DR, Palmer RMJ, Moncada S. Increased )]TJ
0 Tc 1.35 -1.25 Td
(concentrations of nitrite in synovial fluid and serum samples suggest)Tj
T*
[(increased nitric oxide synthesis in rheumatic diseases. )54.9 (Ann Rheum)]TJ
T*
(Dis 1992;51:1219-22.)Tj
-0.00011 Tc -1.35 -1.25 Td
[(5.)-600.1 (Amin )54.8 (AR, )54.8 (Attur M, )54.8 (Abramson SB. Nitric oxide synthase and)]TJ
0 Tc 1.35 -1.25 Td
(cyclooxygenases: distribution, regulation, and intervention in)Tj
T*
[(arthritis. Curr Opin Rheumatol 1999;1)36.9 (1:202-9.)]TJ
31.65 79.671 Td
[(6.)-600 (Jenkinson CP)110.8 (, Grody )17.7 (WW)91.8 (, Cederbaum SD. Comparative properties)]TJ
1.35 -1.25 Td
[(of ar)17.8 (ginases. Comp Biochem Physiol B Biochem Mol Biol)]TJ
0 Tw T*
[(1996;1)36.9 (14:107-32.)]TJ
0.02499 Tw -1.35 -1.25 Td
[(7.)-600 (Gotoh )17.8 (T)74 (, )54.9 (Araki M, Mori M. Chromosomal localization of the human)]TJ
1.35 -1.25 Td
[(ar)17.8 (ginase II gene and tissue distribution of its mRNA. Biochem)]TJ
T*
(Biophys Res Commun 1997;233:487-91.)Tj
-0.00011 Tc -1.35 -1.25 Td
[(8.)-600.1 (Corraliza IM, Soler G, Eichmann K, Modolell M. )54.8 (Ar)17.7 (ginase)]TJ
1.35 -1.25 Td
(induction by suppressor of nitric oxide synthesis \(IL-4, IL-10 and)Tj
-0.0002 Tc 0 Tw T*
(PGE)Tj
0 Tc 5.2 0 0 5.2 350.7094 631.8893 Tm
(2)Tj
0.0249 Tw 8 0 0 8 353.3094 634.5293 Tm
(\) in murine bone-marrow-derived macrophages. Biochem)Tj
-2.2137 -1.25 Td
(Biophys Res Commun 1995;206:667-73.)Tj
-1.35 -1.25 Td
[(9.)-600 (Louis CA, Mody )17.7 (V)129.1 (,)0.1 ( Henry )17.7 (WL, Reichner JS, )54.8 (Albina JE. Regulation)]TJ
-0.00011 Tc 1.35 -1.25 Td
[(of ar)17.7 (ginase isoforms I and II by IL-4 in cultured murine peritoneal)]TJ
0 Tc T*
[(macrophages. )54.9 (Am J Physiol 1999;276:237-42.)]TJ
-0.00011 Tc -1.85 -1.25 Td
[(10.)-600.1 (Ochoa JB, Bernard )54.8 (AC, O\222Brien )17.7 (WE, et al. )54.8 (Ar)17.7 (ginase I expression)]TJ
0 Tc 1.85 -1.25 Td
[(and activity in human mononuclear cells after injury)64.9 (. )54.8 (Ann Sur)17.8 (g)]TJ
0 Tw T*
(2001;233:393-9.)Tj
-0.00011 Tc 0.02499 Tw -1.8131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-600.1 (Modolell M, Corraliza IM, Link F)79.7 (,)-0.1 ( Soler G, Eichmann K.)]TJ
0 Tc 1.8131 -1.25 Td
[(Reciprocal regulation of the nitric oxide synthase/ar)17.8 (ginase balance)]TJ
T*
[(in mouse bone marrow-derived macrophages by )17.8 (Th1 and )17.8 (Th2)]TJ
T*
[(cytokines. Eur J Immunol 1995;25:1)36.8 (101-4.)]TJ
-0.00011 Tc -1.85 -1.25 Td
[(12.)-600.1 (Porembska Z, Zabek J, Grabon )17.7 (W)91.7 (, Rahden-Satron I,)]TJ
0 Tc 1.85 -1.25 Td
[(Baranczyk-Kuzma )54.9 (A. )54.9 (Ar)17.8 (ginase isoforms in human colorectal cancer)54.9 (.)]TJ
T*
[(Clin Chim )54.9 (Acta 2001;305:157-65.)]TJ
-0.00011 Tc -1.85 -1.25 Td
[(13.)-600.1 (Bivalacqua )17.7 (TJ, Hellstrom )17.7 (WJ, Kadowitz PJ, Champion HC.)]TJ
0 Tc 1.85 -1.25 Td
[(Increased expression of ar)17.8 (ginase II in human diabetic corpus)]TJ
T*
(cavernosum: in diabetic-associated erectile dysfunction. Biochem)Tj
T*
(Biophys Res Commun 2001;283:923-37.)Tj
-1.85 -1.25 Td
[(14.)-600 (W)79.8 (addington SN, Cattell )17.8 (V)129.1 (. )54.9 (Ar)17.8 (ginase in glomerulonephritis. Exp)]TJ
1.85 -1.25 Td
(Nephrol 2000;8:128-34.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(15.)-600.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.85 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.85 -1.25 Td
[(16.)-600 (Schmidt HHHW)91.8 (, Kelm M. Determination of nitrite and nitrate by)]TJ
-0.00011 Tc 1.85 -1.25 Td
(the Griess reaction. In: Feelisch M, Stamler J, editors. Methods in)Tj
0 Tc T*
[(nitric oxide research. Chichester: )17.8 (W)39.8 (iley; 1996:491-7.)]TJ
-1.85 -1.25 Td
[(17.)-600 (T)69.8 (aylor BS, de )17.7 (V)111.1 (era ME, Ganster R)54.9 (W)91.8 (, et al. Multiple NF-kappa B)]TJ
1.85 -1.25 Td
(enhancer elements regulate cytokine induction of the human)Tj
T*
(inducible nitric oxide synthase gene. J Biol Chem 1998;)Tj
0 Tw T*
(273:15148-56.)Tj
-0.00011 Tc 0.02499 Tw -1.85 -1.25 Td
[(18.)-600.1 (Sharara )54.8 (AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA,)]TJ
1.85 -1.25 Td
[(W)79.7 (einber)17.7 (g JB. Interferon \(IFN\)-alpha activation of human blood)]TJ
0 Tc T*
(mononuclear cells in vitro and in vivo for nitric oxide synthase)Tj
T*
[(\(NOS\) type 2 mRNA)-220.1 (and protein expression: possible relationship)]TJ
T*
[(of induced NOS 2 to the anti-hepatitis C ef)17.8 (fects of IFN-alpha in)]TJ
T*
(vivo. J Exp Med 1997;186:1495-502.)Tj
-1.85 -1.25 Td
[(19.)-600 (Y)111.1 (ukioka K, )17.8 (W)79.8 (akitani S, )36.9 (Y)111.1 (ukioka M, et al. Polyamine levels in)]TJ
1.85 -1.25 Td
(synovial tissues and synovial fluids of patients with rheumatoid)Tj
T*
(arthritis. J Rheumatol 1992;19:689-92.)Tj
-1.85 -1.25 Td
[(20.)-600 (T)69.8 (akeba )36.8 (Y)129.2 (, Suzuki N, )17.8 (W)79.8 (akisaka S, )17.8 (T)69.8 (akeno )54.9 (A, )54.9 (Asai )17.8 (T)74 (, Sack )17.8 (T)74 (.)]TJ
1.85 -1.25 Td
[(Involvement of cAMP)-238.1 (responsive element binding protein \(CREB\))]TJ
T*
(in the synovial cell hyperfunction in patients with rheumatoid)Tj
T*
(arthritis. Clin Exp Rheumatol 2000;18:47-55.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(21.)-600.1 (Shearer JD, Richards JR, Mills CD, Caldwell MD. Dif)17.7 (ferential )]TJ
0 Tc 1.85 -1.25 Td
[(regulation of macrophage ar)17.8 (ginine metabolism: a proposed role in)]TJ
T*
[(wound healing. )54.9 (Am J Physiol 1997;272:E181-90.)]TJ
-1.85 -1.25 Td
[(22.)-600 (Goddard DH, Grossman SL, )17.7 (W)39.8 (illiams )17.7 (WV)128.9 (, et al. Regulation of)]TJ
-0.00011 Tc 1.85 -1.25 Td
(synovial cell growth. Coexpression of transforming growth factor)Tj
0 Tc T*
(beta and basic fibroblast growth factor by cultured synovial cells.)Tj
T*
(Arthritis Rheum 1992;35:1296-303.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(23.)-600.1 (Jacobs RA, Perrett D, )54.8 (Axon JM, Herbert KE, Scott DL. Rheumatoid)]TJ
0 Tc 1.85 -1.25 Td
(synovial cell proliferation, transformation and fibronectin secretion)Tj
T*
(in culture. Clin Exp Rheumatol 1995;13:717-23.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(24.)-600.1 (Aigner )17.7 (T)73.9 (, Stoss H, )17.7 (W)79.7 (eseloh G, Zeiler G, von der Mark K. )54.8 (Activation)]TJ
0 Tc 1.85 -1.25 Td
(of collagen type II expression in osteoarthritic and rheumatoid)Tj
0.0072 Tw T*
[(cartilage. V)60.1 (irchows )37.1 (Arch )-17.8 (1992;62:337.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Corraliza and Moncada: )17.7 (Ar)36.8 (ginase II in arthritis)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2265)Tj
ET
0 0 0 0 scn
/GS0 gs
101.59 59.08 407.5 -10.83 re
f*
0.5 w
101.59 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
94 0 obj
<>
endobj
171 0 obj
<>
endobj
56 0 obj
<>
endobj
32 0 obj
<>
endobj
54 0 obj
<>
endobj
53 0 obj
<>
endobj
85 0 obj
<>stream
HVpTι&BxIw{I$kxHx@@y$ ] HL,AR:TJ5 S
a)A{M م 5P7
S\t\Q*v#06 ~UTH?*/m@i).0#P/WFm(+r(͢O2
"k@仗/Z5"?}Ոr&+o뉧ż,"#_a+T|N&Ds(壓Rbl[VP˄;Xg[IZqoa?c ЈHV=E!.zBb3V␋"2]2EŨ
\*400v:&"eu
'Gbgx묝pc0#7fL('7G|nb^N aD ܩA#VHDOOq#d^ b$
kଘ!)VS"x,"Pф{b[[&5m%4$}c4NlcFfr\!"O!qZzR٭FiݬHdea6D{fϝO'k#Dw)rV$r<(VuzٺB" '+ٗȇ`G>*De6{؇4M8E!2}}!H#
9L^PҔ!\V˕M$ߕ埥)ȣMT*JҟëQ)~eN٦lWv(PN(PTj_=Aв|XzmvN0sssY-;~7^D}6yLzqY2N/ԩ8'QWnGxFHB:F)N{
wu-8 u+ϱh5ao|GpU
xT2y~O^=3s>㙔/\zI]bc;w!}dmÜMU@#GmSgx}!3iK-Kdi<Q r^C7z:9Fn6cCk5%Ĵ#rCƕ^sDeYa7qCvdK8^3FNH${fބoNНnE,0}Z{(n:3 V
k0˗QlޢCk䘱]{>Zy״*Ҕ#%,-kȍ~AgL+X[(17G7ÍaFY`5OXڝi
|ПUOkMqKX&PP{[2gyԾ!9jbb^@T쯒,hƧP/}vM(C|h*q$G}{i7LK3SSsm"!!A_wzŨ.,XG[уYd̚ -Y]vÓVhJHokji=Ea)?b:y"g%!u H0w%(ZJRdeJuS*$$>|z
O!_y̶n"R,+IHIHϓ2SGf<;O81iQjVZTQgZՎuu!?N;c=)B[JRsCڒ=H=h#qEJ/D²sw3f&EXM%^q"UJQ'!5vvΏr
o1~H-B4՞` *}D$ͤΤryUyzz7u\+eYJ[&~`a[2`ljblR0Ĵƀ!N]@ s$f&I@)`J`?
4%tq2t
Գ+QL#3owϷg={.D8~KuzZp%B]3("߯>QG`;@mD)vC-H*v#A
.rk#1qm1ւ䰘 غgǏ;0/
ah.?5'!˿'%:G ': &cG!r2oXI(W,~>X;dR Z$[;3oc,w!s0N%EBޕe,CKPPvFA:'C0tB~PH$ZK
9 `S~ BXS B `R^ Q!o)
B^0(@ t
(d7V! P+d'J!; . H!R: 1;j;įH˸smZ}feXmrkdjm'ūvn]\k${8 7Ċq^8\D<ɵRfN}:qN\S'Ĝ:Q$K^bn+zt?zpy4<×fIQYZ?A~5_H8x
5q<:R4\J2a4`E4%^
C¼KS=I-gSC4a %Qz/֬z\j8
F^8^-⌔K*Bg8+xy?9QzIQ(ʫNwBR4GE/t'r'IaH.S;N!np3oRޜy&j:mϹ&>R8Cx4(7Z ފ#09asxfNgYOMjx@?A&y /%\.